Melane Sampson, Author at BioTuesdays

Developments

FDA clears Pentixapharm IND for cardiovascular diagnostic program

Pentixapharm Holding (Frankfurt Prime Standard: PTP) has announced that the FDA has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant...

June 9, 2026

Developments

ZEO adds nine experts in regenerative and longevity medicine to advisory board

ZEO ScientifiX (OTCQB: ZEOX) has announced the expansion of its medical advisory board with the addition of nine physicians and scientific innovators across key disciplines in regenerative and longevity medicine. The...

June 9, 2026

Feature

Healing the Hero rewiring trauma through neurolinguistic programming

The nonprofit organization Healing the Hero is bringing hope to U.S. military personnel, veterans, first responders, and Gold Star Families by leveraging neurolinguistic programming (NLP)-informed methods to directly...

June 9, 2026

Developments

Eledon reports insulin independence in islet transplant patients treated with tegoprubart

Eledon Pharmaceuticals (NASDAQ: ELDN) announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free...

June 8, 2026

Developments

Shattuck announces Phase 1 results for SL-325 antibody

Shattuck Labs (NASDAQ: STTK) has announced data from its Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics, and immunogenicity of SL-325, its lead DR3 blocking...

June 8, 2026

Developments

ANSM grants clearance for Anteris trial of transcatheter heart valve

Anteris Technologies Global (NASDAQ: AVR; ASX: AVR) has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) enabling patient recruitment to begin in France...

June 8, 2026

Developments

MindBio launches AI software for drug use and fatigue detection

MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has launched its lead commercial software Intox AI for validation and testing of intoxication and fatigue. Intox AI enables new analytical capabilities to...

June 5, 2026

Executive Moves

Tempest appoints Drake Richey and Dr. John Yee to BoD

Tempest Therapeutics (NASDAQ: TPST) has appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its board of directors (BoD), effective June 4, 2026. Mr. Richey and Dr. Yee collectively bring decades...

June 5, 2026

Developments

TelyRx commences trading on OTCQX

TelyRx Holdings (TSX: TELY; OTCQX: TELYF) has announced that its subordinate voting shares will commence trading on the OTCQX Best Market (OTCQX), the premier tier of the OTC Markets Group in the U.S., under the symbol...

June 5, 2026

Executive Moves

Cocrystal appoints James Sapirstein as CEO

Cocrystal Pharma (NASDAQ: COCP) has appointed biopharma industry leader James Sapirstein as chief executive officer (CEO), effective immediately. According to Cocrystal, Mr. Sapirstein will also be appointed to its...

June 4, 2026

Author - Melane Sampson

FDA clears Pentixapharm IND for cardiovascular diagnostic program

ZEO adds nine experts in regenerative and longevity medicine to advisory board

Healing the Hero rewiring trauma through neurolinguistic programming

Eledon reports insulin independence in islet transplant patients treated with tegoprubart

Shattuck announces Phase 1 results for SL-325 antibody

ANSM grants clearance for Anteris trial of transcatheter heart valve

MindBio launches AI software for drug use and fatigue detection

Tempest appoints Drake Richey and Dr. John Yee to BoD

TelyRx commences trading on OTCQX

Cocrystal appoints James Sapirstein as CEO

Subscribe